Watson Pharmaceuticals a leading specialty pharmaceutical company has launched Clarithromycin Extended-Release Tablets, USP in the 500 mg strength to treat or prevent infections caused by susceptible bacteria

Watson's Clarithromycin Extended-Release product is the generic equivalent to Abbott's Biaxin® XL, which is indicated to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Watson Pharmaceuticals develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products.

According to IMS Health data, for the 12-months ending September 2007, Biaxin® XL and its generic equivalents had total U.S. sales of approximately $200 million.  The U.S. Food and Drug Administration granted final approval of Watson's Abbreviated New Drug Application (ANDA) for Clarithromycin Extended-Release on June 24, 2004. Patent infringement litigation related to Watson's ANDA was dismissed with prejudice on July 12, 2007.